Rilonacept (Interleukin-1 Trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: Results of a phase II randomized, double-blind, placebo-controlled trial

Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study

(2011) N. Schlesinger et al.   ANNALS OF THE RHEUMATIC DISEASES

Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis

(2009) R Torres et al.   ANNALS OF THE RHEUMATIC DISEASES

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

(2009) R Terkeltaub et al.   ANNALS OF THE RHEUMATIC DISEASES

The practical management of gout

(2009) H. R. SCHUMACHER et al.   CLEVELAND CLINIC JOURNAL OF MEDICINE

The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis

(2009) Daniel E. Furst   SEMINARS IN ARTHRITIS AND RHEUMATISM

Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies

(2008) Hal M. Hoffman et al.   ARTHRITIS AND RHEUMATISM